TRPM2 and atherosclerosis: Unlike most previous vaccine-related studies, which target LDL-related antigens [10,11,12,13,14,15], we targeted TRPM2, which is expressed in multiple atherosclerosis-related cell types (monocytes, macrophages, vascular endothelial cells and vascular smooth muscle cells) and is involved in ROS-related vascular inflammation [17,18,19,20,21,22].